Jul 27 2021 Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential View
Jul 20 2021 Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC View
Jun 15 2021 Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting View
Jun 07 2021 Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference View
Jun 01 2021 Relmada Therapeutics Announces Participation in Jefferies Virtual Healthcare Conference View
May 26 2021 Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting View
May 12 2021 Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results View
May 06 2021 Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021 View
May 01 2021 Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021 View
Apr 29 2021 Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting View
